Key Takeaways
- PROSEEK failure resets the pipeline: Vodobatinib missed its primary endpoint in Parkinson’s, the trial is closed, and management advises investors to discount the asset fully. The company’s largest program is now parked.
- Cash runway is tight at 12–15 months: Current cash (~$20M) plus credit lines fund operations into mid-2025, with no near-term equity raise planned. Milestones from Vibozilimod and Phenobarbital could extend that window.
- CML out-licensing becomes a non-dilutive funding catalyst: SCO-088 and Vodobatinib’s leukemia program are both targeted for licensing deals this financial year, explicitly to raise capital for the early-stage pipeline.
- Early-stage pipeline is now the equity story: SCD-153 (alopecia areata) just entered Phase I, SBO-154 (ADC) targets an IND by March 2025, and Vibozilimod’s atopic dermatitis readout is due in Q4 2024.
- What to watch next quarter: The full PROSEEK data analysis, any progress on the CML licensing process, and the Vibozilimod SOLARES top-line results expected in Q4 2024.
The PROSEEK Failure: What Happened and What It Means
- Primary endpoint missed decisively: Both low-dose and high-dose Vodobatinib arms failed to show a statistically significant change in MDS-UPDRS Part III at week 40 versus placebo. Key secondary endpoints trended similarly.
- Placebo response broke the trial: An extraordinarily high placebo response was observed, with the placebo curve staying flat for almost the entire study period. This overwhelmed any potential treatment signal.
- Biomarker data was conflicting: Neurofilament light and alpha-synuclein assays from cerebrospinal fluid produced inconsistent results, offering no clear rescue narrative.
- Trial closed, all related work parked: The Lewy Body Dementia investigator-initiated trial and all preclinical back-up series for Vodobatinib have been halted. A full data analysis is promised by Q2 of this financial year.
- PK analysis not yet performed: Blood and CSF samples are available but have not been analyzed for peripheral and brain exposure. Management did not answer whether confirming blood-brain barrier penetration would hold value if proven.
- Retrial possibility described as very remote: Management said all options remain possible until the full dataset is reviewed, but characterized the likelihood as very remote given the primary and secondary endpoint trends seen.
Raghavan: "That was indeed a disappointing outcome, and certainly not what we hoped for our patients, especially after having generated significant body of evidence in preclinical model systems... demonstrating the neuroprotective role of Vodobatinib in multiple pre-clinical studies."
Financial Position and Runway
- Runway extends 12–15 months: The current cash balance of approximately $20 million, combined with an approved credit facility, funds operations into mid-2025. This factors in cost savings from deprioritizing the Vodobatinib Parkinson’s program.
- No near-term equity raise contemplated: Management explicitly stated it is not planning a dilutive capital raise in the near term.
- Non-dilutive catalysts are critical: Milestone payments from Vibozilimod (on successful Phase II completion) and growing Phenobarbital (SEZABY) revenues are the identified sources to augment the runway beyond the 12–15 month window.
- Portfolio reset underway: The company will review its entire clinical and preclinical portfolio to identify and prioritize high-value programs while optimizing the cost base to extend the cash runway.
Raghavan: "Obviously these results represent a setback for SPARC which will pose questions on certain parts of our portfolio and challenge our ability to pursue an aggressive R&D agenda."
Leukemia Franchise: The Licensing Pivot
- Vodobatinib CML program is safe but deprioritized: The PROSEEK safety profile is supportive of the lower leukemia dose, so the Parkinson’s failure has no negative read-through. However, management believes it is not an appropriate use of SPARC’s capital to take the program to US regulatory approval itself.
- Out-licensing process initiated: The company is actively looking for licensing partners for Vodobatinib in all leukemia settings (front-line, earlier-line, and last-line). The objective is to finalize a deal this financial year.
- SCO-088 also targeted for a deal: A licensing deal for SCO-088 in CML is targeted in this financial year, with the explicit goal of raising non-dilutive capital to fund SCD-153 and SBO-154 development. FDA discussions on a registration study design were happening the same day as the call.
- CML opportunity sized at several hundred million dollars: Management disclosed this is significantly smaller than the multi-billion-dollar Parkinson’s opportunity that was lost, framing the licensing strategy as a capital allocation decision.
- Comparator and trial design depend on FDA feedback: If a comparative study is required, Bosutinib is the most relevant comparator, but the final design, including the treatment line tested, will be determined after agency discussions.
Early-Stage Pipeline: The New Value Drivers
- SCD-153 enters the clinic for alopecia areata: A Phase I single ascending dose trial in healthy volunteers is underway in India. The development plan skips a traditional 14-day multiple ascending dose study and moves directly into a patient study in alopecia areata, which could provide an early efficacy signal.
- SCD-153 proof-of-concept strategy: A Phase II study is planned in two parts: an India-based study of up to 250 patients with an interim analysis, followed by global expansion if proof-of-concept is achieved. Management views this India-based data package as an ideal licensing opportunity.
- SBO-154 ADC manufacturing scale-up in progress: The company is working with a San Diego-based CDMO to scale up manufacturing for the clinical program. Non-clinical studies have started, and an IND filing is targeted before the end of the current financial year (by March 2025).
- Vibozilimod atopic dermatitis readout in Q4 2024: The SOLARES trial top-line results are expected in the fourth quarter of 2024. The psoriasis program is behind atopic dermatitis, and data is not expected this year.
Commercial Products: Incremental, Not Transformational
- Phenobarbital (SEZABY) launched, exclusivity fight ongoing: The product is launched, but a meaningful revenue takeoff depends on establishing market exclusivity and removing unapproved competing products. Management expects this to take 2–3 years total, with one year already completed.
- FDA case is about a voucher, not the product launch: The company filed a case against the FDA on April 2 regarding the denial of a pediatric rare diseases voucher for Phenobarbital. Management declined to discuss the case further as it is sub judice.
- Citizen petition timeline uncertain: The FDA has asked for more time on the citizen’s petition regarding unapproved competitors, calling it a complex matter, and has not set a specific timeline for action. SPARC is adding leverage by working with patient advocacy groups and engaging directly with unauthorized manufacturers.
- ELEPSIA transitioning partners: The product is in the process of moving to a different commercialization partner, and the transition is not yet finalized.
- PDP-716 refiling in September: The company plans to refile around September.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| PROSEEK full data analysis | Complete analysis of all data including PK | Q2 FY25 |
| Vodobatinib CML out-licensing | Finalize licensing partner for all leukemia settings | This financial year |
| SCO-088 licensing deal | Partner asset to raise non-dilutive capital | This financial year |
| SCD-153 Phase I completion | Complete single ascending dose and patient study | By FY25 |
| SCD-153 early patient study | Study in alopecia areata patients in India | By FY26 |
| SBO-154 IND filing | File IND for ADC program | Before end of current financial year (by Mar 2025) |
| Vibozilimod SOLARES top-line results | Atopic dermatitis Phase II data readout | Q4 2024 |
| PDP-716 refiling | Refiling with regulator | September 2024 timeline |
| Cash runway | Current cash plus credit funds operations | 12–15 months |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| PROSEEK primary endpoint | Not met (change in MDS-UPDRS Part III at week 40 vs placebo) |
| PROSEEK patients reviewed in interim analysis | 442 of 513 randomized patients completed Part I by March 2024 |
| PROSEEK trial status | Closed based on statistical projections of unlikely benefit in overall population |
| PROSEEK full analysis expected | Q2 FY25 |
| PROSEEK total budget | $45 million range, with savings expected from early termination |
| PROSEEK spend to date | In excess of $35 million, between $35 million and $40 million, closer to $35 million |
| Current cash balance | Around $20 million |
| Cash runway | 12–15 months from current cash and approved credit, factoring in cost savings from reprioritization |
| SCO-088 (Vodobatinib CML) status | Phase 2 completed, registration study design discussions with USFDA underway |
| SCO-088 licensing objective | Targeting this financial year |
| CML opportunity size | Several hundred million dollars (vs several billion for Parkinson's) |
| Vibozilimod SOLARES AD top-line results | Q4 2024 |
| SCD-153 Phase 1 completion | By FY25, early patients' study in Alopecia Areata in India by FY26 |
| SBO-154 IND filing | By end of current financial year |
| Phenobarbital exclusivity expected | End of second year or beginning of third year of launch |